Previous Close | 5.79 |
Open | 5.64 |
Bid | 5.88 x 800 |
Ask | 5.99 x 1300 |
Day's Range | 5.60 - 5.97 |
52 Week Range | 4.30 - 17.17 |
Volume | |
Avg. Volume | 124,383 |
Market Cap | 30.99M |
Beta (5Y Monthly) | 1.56 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | May 12, 1980 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for AIKI
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on June 23, 2022, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ's requirements when the closing bid price for the Company's common stock was at o
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") announced the formation of a wholly owned subsidiary with the purpose of making strategic investments and acquisitions across the fintech and financial services industries. The new subsidiary is expected to be the centerpiece of a long-range plan to diversify AIkido's business beyond biotechnology, in order to reduce volatility and mitigate risk while increasing revenue and enhancing shareholder value.
The Board and Management Clearly Have Lost the Confidence of Stockholders Concerned that Allowing the Status Quo to Continue Will Result in More Insider Dealing and Destruction of Stockholder Value Believes the Commencement of an Orderly Process to Sell Company Assets and Return Capital to Stockholders Represents the Best Path Forward to Preserve Stockholder Value NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Shalom Auerbach, a significant stockholder of AIkido Pharma Inc. (NASDAQ: AIKI) beneficia